AB Science SA (0Q77) AI Stock Analysis

AB Science SA

(LSE:0Q77)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRecent revenue growth indicates that AB Science is expanding its reported business base despite remaining loss-making. Continued top-line improvement would provide a stronger foundation for operating leverage and could increase the commercial value of its development portfolio over the next several quarters.

Negative Factors

Persistent UnprofitabilityPersistent operating and net losses show that the business remains far from breakeven and that revenue is not yet sufficient to support its cost base. Continued losses can consume financial resources, limit internal reinvestment, and make sustainable earnings dependent on future development or commercial progress.

AB Science SA (0Q77) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 82.04M
Dividend Yield: ―
Average Volume (3M): 2,963
Price to Earnings (P/E): -6.7
Beta (1Y): 0.55
Revenue Growth: 12.66%
EPS Growth: 44.01%
Country: UK
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

AB Science SA Business Overview & Revenue Model

Company Description

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibit...

AB Science SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0Q77 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:IPN	71Outperform	EUR 13.04B	25.42	11.33%	1.02%	13.63%	14.45%
FR:SAN	70Outperform	EUR 95.65B	24.39	5.52%	10.45%	15.30%	-35.58%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:IPH	47Neutral	EUR 140.30M	-2.46	152.56%	―	-29.48%	7.91%
FR:OSE	43Neutral	EUR 45.93M	-1.16	-96.73%	―	-96.25%	-197.89%
FR:ALCLS	43Neutral	EUR 75.07M	-1.78	-94.14%	―	-5.98%	-8.67%

* Healthcare Sector Average

Performance Comparison

GB:0Q77 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0Q77	Ab Science	0.55	-0.62	-52.65%
FR:IPH	Innate Pharma S.A.	1.26	-0.39	-23.51%
FR:IPN	Ipsen	157.60	36.39	30.02%
FR:OSE	OSE Immunotherapeutics	1.95	-3.75	-65.75%
FR:SAN	Sanofi	79.74	-2.60	-3.15%
FR:ALCLS	Cellectis SA	1.04	-1.90	-64.63%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AB Science SA AI Stock Analysis